Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor
10.3760/cma.j.issn.0253-3766.2020.01.007
- VernacularTitle: 恶性肿瘤患者免疫治疗相关肝不良事件的影响因素
- Author:
Shuluan LI
1
;
Xiaoping GAO
2
;
Qianqi CHEN
2
;
Xiaohong FU
2
;
Yan ZHAO
2
;
Jiangman DUAN
2
;
Yueqiang TANG
2
;
Jie SUN
2
;
Junling LI
3
;
Qiming ZHOU
2
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China
2. Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China
3. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Clinical Trail
- Keywords:
Malignant neoplasms;
Immune checkpoint inhibitor;
Immune treatment-related hepatic adverse events
- From:
Chinese Journal of Oncology
2020;42(1):50-54
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical features and risk factors of hepatic injury due to immune checkpoint inhibitors (CPI) therapy in malignant tumor.
Methods:Data of 112 patients (64 men and 48 women) who received CPI between January 2016 and March 2019 in Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Hospital, and Huazhong University of Science and Techology Union Shenzhen Hospital were retrospectively collected. The median age of these patients was 60 years.
Results:Hepatic adverse events were observed in 30 patients out of 112 patients (26.8%). Among them, the incidence of grade 3-5 hepatic adverse events were 7.14% (8/112). The median time of hepatic adverse event occurrence was 3 weeks (2-30) after undergoing therapy. The results of univariate and multivariate analyses showed that liver cancer was attributed to the CPI induced hepatitis (P<0.05). Patients with severe hepatic injury got almost complete resolution after receiving methlprednisolone for 4 to 6 weeks.
Conclusion:Live cancer is the risk factor of CPI-related hepatic adverse events.
